daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

ESMO Open · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles